1. Home
  2. Medical News
  3. Men's Health
advertisement

Brazilian Study Examines 12-Month Outcomes After BPH Ablation

Illustration of enlarged prostate transition zone tissue with a subtle treated area after BPH ablation
11/06/2026

Key Takeaways

  • Men treated in Brazilian outpatient centers for medication-refractory or medication-intolerant BPH symptoms generally reported preserved antegrade ejaculation after transperineal ablation.
  • The primary ejaculatory-function score showed no statistically significant change at follow-up.
  • Nearly all treated men met the urinary response definition without retreatment, and urinary flow improved.
  • No Clavien–Dindo grade III or higher complications occurred, although early urinary symptoms were recorded.
Investigators conducted a prospective bicenter study of men with medication-refractory or medication-intolerant BPH symptoms at two outpatient interventional-radiology centers in Brazil, without randomization or a control group. Of 40 men screened, 34 underwent treatment, and all treated men completed yearlong clinical follow-up. Consecutive participants had bothersome lower urinary tract symptoms despite BPH medication, could not tolerate it, or were dissatisfied with it. Bilateral transperineal radiofrequency ablation was performed under sedation, local blocks, and real-time transrectal ultrasound guidance, maintaining a safety margin from the urethra and bladder floor. Routine catheterization was avoided, with same-day discharge intended. The prespecified primary outcome was the change over a year in the Male Sexual Health Questionnaire–Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF) function score. Patient-reported antegrade ejaculation was recorded separately. The secondary composite assessed at least a 30% reduction in International Prostate Symptom Score (IPSS) without BPH retreatment at 12 months; response rates were also reported at 6 months.

The paired 12-month MSHQ-EjD-SF function-score change was −0.17 (95% confidence interval [CI] −1.09 to 0.75; P=0.704). Scores declined numerically, but the change was not statistically significant; nonsignificance does not establish equivalent function. The baseline function questionnaire was available for 29 men. Separately, 27 of 30 sexually active men (90%) reported preserved antegrade ejaculation at 12 months, using a different denominator from the baseline questionnaire.

The authors reported a composite response in 33 of 34 men (97.1%) at both 6 and 12 months. Median IPSS fell from 19.5 at baseline to 4.0 at 12 months, with improvement also evident at the intervening assessment. Baseline IPSS was available for 32 men, whereas follow-up IPSS was available for all treated men. Maximum urinary flow rate (Qmax) increased; post-void residual volume (PVR), prostate volume, and prostate-specific antigen (PSA) decreased. Most men (32/34) discontinued BPH-related medicines. One man underwent repeat ablation after an inadequate initial response. No Clavien–Dindo grade III or higher events occurred. Within 30 days, 5 of 34 men (14.7%) had acute urinary retention requiring temporary catheterization, 4 (11.7%) had urinary tract infection, and 12 (35%) had clinically significant dysuria; these events were managed conservatively.

This selected, modest single-arm cohort cannot establish a causal benefit, superiority or equivalence to existing procedures, or durability beyond the observed follow-up. A nonsignificant change in the primary score cannot guarantee maintained ejaculation for every man. The ejaculatory questionnaire has no established minimal clinically important difference in this setting, and questionnaire availability varied. Medication cessation beyond the planned month-one attempt was not fully protocolized. These factors constrain interpretation of the observed sexual and urinary changes.

The authors described concurrent urinary improvement and reported preservation of ejaculation in the treated outpatient cohort. They called for larger, multicenter comparative evaluation with longer follow-up to assess those outcomes.

Clinician Questions

Which men were eligible for outpatient transperineal radiofrequency ablation for BPH?

Eligible men were at least 50 years old, had an IPSS of at least 8 and prostate volume of 30–200 mL, and had BPH symptoms refractory to medication, medication intolerance, or dissatisfaction with BPH medicines.

They also had maximum urinary flow below 15 mL/s or catheter dependence despite medication. Known or suspected prostate cancer, bladder stones, neurogenic bladder, urethral stricture, and uncontrolled systemic disease were exclusions from this outpatient transperineal intervention.

Was erectile function measured after urethra-sparing transperineal ablation for BPH?

Erectile function was not prospectively assessed with the International Index of Erectile Function 5 in men receiving ultrasound-guided, urethra-sparing transperineal radiofrequency ablation for BPH. Ejaculatory function was assessed separately; reported preservation of antegrade ejaculation does not establish whether erectile function was maintained or changed.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free